Clinical trials: Immunosuppression After Kidney Transplantation
Kidney Failure, Transplant Recipient (Kidney)
Tolerance Through Mixed Chimerism (Sip-Tego)
This is an open-label, single-institution study to assess the safety and the efficacy of the Sip-Tego regimen for the induction of donor-specific immunologic unresponsiveness to a renal allograft.
- Conditions
- Kidney Failure, Transplant Recipient (Kidney), Transplant Tolerance, Immunosuppresion
- Trial name
- NCT06972069
- Testing
- Combined Kidney/Bone Marrow Transplant, Donation of Kidney / Bone Marrow, Conditioning Regimen (Rituxan, Siplizumab (or ATGAM), Cyclophosphamide, Tegoprubart)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Tatsuo Kawai, MD, PhD
Kidney Transplant, Kidney Transplant Failure and Rejection
(TNX-1500) in Kidney Transplant Recipients
The primary objective is to investigate the safety of TNX-1500, an FC-modified anti-CD154 mAb, in five kidney transplant recipients at 12 months.
- Conditions
- Kidney Transplant, Kidney Transplant Failure and Rejection, Immunosuppression, Immunosuppression After Kidney Transplantation
- Trial name
- TONIX-1500 (NCT07204080)
- Testing
- TNX-1500, Kidney Transplant
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Ayman Al Jurdi, MD
Immunosuppression After Kidney Transplantation
PEL-1235_REN-0176-I (Pelicon)
Aim of this study is to investigate whether in patients following kidney transplantation (>6 months after transplantation), the intra-patient variability of levels of tacrolimus is comparable after administration of tacrolimus…
- Trial name
- Pelicon (NCT01904045)
- Testing
- tacrolimus Advagraf, tacrolimus Prograf
- Where
- Germany
- Volunteers
- 51 people
- Sponsor
- Technical University of Munich
Immunosuppression After Renal Transplantation
Efficacy and Safety of a Reduced Immunosuppression vs. Standard Triple Therapy in Senior Renal Transplant Recipients
Study purpose To establish efficacy and safety of a reduced immunosuppressive therapy with tacrolimus once daily for senior (>65 years of age) renal transplant recipients
- Trial name
- REDUCE (NCT02453867)
- Testing
- Reduced immunosuppression, Tacrolimus, mycophenolate
- Volunteers
- 400 people
- Sponsor
- Klemens Budde